Loading
AKR1C3 is an enzyme that makes potent male hormones and that some cancers carry in large amounts. Rather than blocking it, prodrugs use it as a key: they stay inactive until AKR1C3 inside a tumour cell converts them into a DNA-damaging drug. This dossier gathers the 1 product (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
NADPH-dependent reductase with broad ketosteroid substrate specificity (UniProt P42330); in these medicines it is the activating enzyme, not the thing inhibited.
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"AKR1C3" OR ABSTRACT:"AKR1C3" OR TITLE:"aldo-keto reductase family 1 member C3" OR ABSTRACT:"aldo-keto reductase family 1 member C3" OR TITLE:"HSD17B5" OR ABSTRACT:"HSD17B5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AKR1C3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/akr1c3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/akr1c3.json. Licence CC BY-NC 4.0.